Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
33 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Virobay Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Virobay Inc. - Product Pipeline Review - 2014', provides an overview of the Virobay Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Virobay Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Virobay Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Virobay Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Virobay Inc.'s pipeline products Reasons to buy - Evaluate Virobay Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Virobay Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Virobay Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Virobay Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Virobay Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Virobay Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Virobay Inc. Snapshot 5 Virobay Inc. Overview 5 Key Information 5 Key Facts 5 Virobay Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Virobay Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Out-Licensed Products 11 Out-Licensed Products/Combination Treatment Modalities 12 Virobay Inc. - Pipeline Products Glance 13 Virobay Inc. - Clinical Stage Pipeline Products 13 Phase I Products/Combination Treatment Modalities 13 Phase 0 Products/Combination Treatment Modalities 14 Virobay Inc. - Early Stage Pipeline Products 15 Preclinical Products/Combination Treatment Modalities 15 Discovery Products/Combination Treatment Modalities 16 Virobay Inc. - Drug Profiles 17 VBY-036 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 VBY-129 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 VBY-376 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 VBY-285 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 VBY-825 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 VBY-X 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Small Molecule to Inhibit Cathepsin Protease for Alzheimer's disease 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Small Molecule to Inhibit Cathepsin Protease for Cancer 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Virobay Inc. - Pipeline Analysis 25 Virobay Inc. - Pipeline Products by Target 25 Virobay Inc. - Pipeline Products by Route of Administration 26 Virobay Inc. - Pipeline Products by Molecule Type 27 Virobay Inc. - Pipeline Products by Mechanism of Action 28 Virobay Inc. - Recent Pipeline Updates 29 Virobay Inc. - Dormant Projects 30 Virobay Inc. - Locations And Subsidiaries 31 Head Office 31 Other Locations & Subsidiaries 31 Appendix 32 Methodology 32 Coverage 32 Secondary Research 32 Primary Research 32 Expert Panel Validation 32 Contact Us 33 Disclaimer 33
List of Tables Virobay Inc., Key Information 5 Virobay Inc., Key Facts 5 Virobay Inc. - Pipeline by Indication, 2014 8 Virobay Inc. - Pipeline by Stage of Development, 2014 9 Virobay Inc. - Monotherapy Products in Pipeline, 2014 10 Virobay Inc. - Out-Licensed Products in Pipeline, 2014 11 Virobay Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 12 Virobay Inc. - Phase I, 2014 13 Virobay Inc. - Phase 0, 2014 14 Virobay Inc. - Preclinical, 2014 15 Virobay Inc. - Discovery, 2014 16 Virobay Inc. - Pipeline by Target, 2014 25 Virobay Inc. - Pipeline by Route of Administration, 2014 26 Virobay Inc. - Pipeline by Molecule Type, 2014 27 Virobay Inc. - Pipeline Products by Mechanism of Action, 2014 28 Virobay Inc. - Recent Pipeline Updates, 2014 29 Virobay Inc. - Dormant Developmental Projects,2014 30 Virobay Inc., Other Locations 31
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.